Congestive heart failure and genomic medicine: A look into the 21st century

Cardiovascular Drugs and Therapy

Volumn 11, Issue 6, 1997, Pages 713-717

  Feuerstein, Giora Z ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST;

CONGESTIVE HEART FAILURE; COST OF ILLNESS; DEVELOPING COUNTRY; EDITORIAL; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; NEUROENDOCRINE SYSTEM; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE;

GENE THERAPY; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0031469617     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007716021473     Document Type: Editorial

References (5)

1. Dargie HJ, Reid JL. Cardiovascular remodeling: Implications of clinical management of heart failure. Clin Cardiol 1996;19(Suppl. 1).
2. Arber S, Hunter JJ, Ross J, et al. Deficient mice exhibit a disruption of cardiac cytsarchitectural organization, dilated cardiomyopathy and heart failure. Cell 1997;88;393-403.
3. Parker M, Bristow MR, Cohn JN, et al. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
4. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
5. Haseltine WA. Discovery of genes for new medicines. Scientific American 1997;276(3):92-97.